• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by MedAvail Holdings Inc.

    11/15/23 4:11:50 PM ET
    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $MDVL alert in real time by email
    NT 10-Q 1 nt10-qseptember302023.htm NT 10-Q Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 12b-25
    NOTIFICATION OF LATE FILING
    OMB Number:
    SEC File Number:
    CUSIP: 58406B103

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
    ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
    For Period Ended: September 30, 2023

    ☐ Transition Report on Form 10-K    
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K    
    ☐ Transition Report on Form 10-Q

    For the Transition Period Ended: N/A

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A


    PART I - REGISTRANT INFORMATION

    MEDAVAIL HOLDINGS, INC.
    Full Name of Registrant
    Former Name if Applicable
    4720 East Cotton Gin Loop, Suite 220
    Address of Principal Executive Office (Street and Number)
    Phoenix, Arizona 85040
    City, State and Zip Code




    ______________________________________________________________________________________

    PART II - RULES 12b-25(b) and (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

    ☐(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-CEN, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    ______________________________________________________________________________________

    PART III - NARRATIVE

    State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or other transition report or portion thereof, could not be filed within the prescribed period.

    MedAvail Holdings, Inc. is unable to file its Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2023 by the November 14, 2023 filing deadline. We require additional time to complete the preparation and corresponding review of our condensed consolidated financial statements as of and for the quarter ended September 30, 2023. During the quarter ended September 30, 2023 and in the subsequent period during which we prepare our financial statements and related disclosures for inclusion in the Form 10-Q, we have experienced delays in new partner contracting, the deployment of our MedCenter™ products by our partners and in integration services for contracted MedCenter units. The cumulative effect of these delays, in the absence of favorable developments in the future or a supplemental capital raise within the next twelve months, could have an adverse impact on our projections for liquidity during 2024. These potential adverse effects on our liquidity require us to perform more extensive and complex procedures to assess the potential impact of these effects on our financial statements and the impact of liquidity financing options, for which we need additional time prior to filing our Form 10-Q.

    Forward-Looking Statements

    Certain statements in this 12b-25, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our projections for liquidity, the potential impairment of long-lived assets and the timing for filing the Form 10-Q. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause actual results to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to risks related to completion of our condensed consolidated financial statements for inclusion in the Form 10-Q. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates concerning those or other forward-looking statements.

    ______________________________________________________________________________________

    PART IV - OTHER INFORMATION

    (1) Name and telephone number of person to contact in regard to this notification

    Ramona Seabaugh(877)830-0826
    (Name)(Area Code)(Telephone Number)

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), been filed? If answer is no, identify report(s). ☒ YES ☐ NO

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statement to be included in the subject report or portion thereof? ☐ YES ☒ NO

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
    ___________________________________________________________________________________________________________________








    MEDAVAIL HOLDINGS, INC.
    (Name of Registrant as Specified in Charter

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: November 15, 2023
    By:/s/ Ramona Seabaugh
      
    Ramona Seabaugh
    Chief Financial Officer

    Get the next $MDVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13G/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      2/14/24 1:51:16 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13D/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13D/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      2/6/24 5:15:40 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13D/A filed by MedAvail Holdings Inc. (Amendment)

      SC 13D/A - MedAvail Holdings, Inc. (0001402479) (Subject)

      6/21/23 5:15:32 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Leadership Updates

    Live Leadership Updates

    See more
    • MedAvail Strengthens Leadership Team

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail") a technology-enabled pharmacy company, today announced the appointment of industry leaders Steven Hess to Executive Vice President, General Manager, of SpotRx and Bob McClune to Senior Vice President of Data and Analytics. "We are pleased to have Steven join our senior leadership team. Steven's extensive pharmacy experience across retail and specialty will be integral in leading our strategies to drive profitable growth and optimize our SpotRx hub pharmacy and MedCenter enabled clinic operations. We also welcome Bob to MedAvail to lead our efforts in optimizing and accelerating data exchanges with our clinic partners," said Mark Doerr, Chi

      2/22/22 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Announces Changes to Executive Management and Board of Directors; Preliminary Fourth Quarter and FY 2021 Results

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), a technology-enabled pharmacy company, today announced that Mark Doerr, RPh, has joined the company as chief executive officer ("CEO") and director, effective January 10, 2022. Mr. Doerr succeeds Ed Kilroy, who retired as CEO and from the board of directors and is moving into an advisory role through March 31, 2022. The company also announced changes to its board of directors and reported preliminary fourth quarter and full year 2021 revenue results. Gerard van Hamel Platerink has stepped down as chairperson of the board of directors. Mr. van Hamel Platerink has served on MedAvail's board of directors since June 2012. He is succeeded by c

      1/11/22 4:15:00 PM ET
      $MDVL
      $ME
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MedAvail Appoints Ramona Seabaugh as Chief Financial Officer

      MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), a technology-enabled pharmacy company, today announced the appointment of Ramona Seabaugh as Chief Financial Officer effective immediately. As a key member of MedAvail's executive leadership team, Ms. Seabaugh will lead the Company's financial operations. "Ramona's pharmacy industry expertise and extensive financial leadership experience will be invaluable in executing our strategy to drive operational and financial performance," said Ed Kilroy, President and Chief Executive Officer of MedAvail. "I am pleased to welcome Ramona to our team, as we continue to expand into new geographies and transform the pharmacy experience

      9/20/21 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MedAvail Announces Agreement with New Orleans-Based St. Thomas Community Health Centers for Deployment of Two M4 MedCenters

      PHOENIX, Nov. 28, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with New Orleans-based St. Thomas Community Health Centers for the deployment of two M4 MedCenter kiosks. St. Thomas operates eight Federally Qualified Health Centers (FQHCs), providing affordable health care to underserved communities across the New Orleans metropolitan area. "We are very excited to announce this new agreement with St. Thomas, building upon our existing infrastructure in the New Orleans area and growing our presence in the FQHC partner channel, where we see significant long-term gro

      11/28/23 7:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

      PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), an innovative pharmacy technology company, announced today that on November 16, 2023, the Company received a delinquency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to have timely filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission. The delinquency notification letter provides that, under Nasdaq rules, the Company now has 60 calendar days to submit

      11/17/23 4:05:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Announces Agreement with ASP Cares for Deployment of Ten M4 MedCenters

      Initial three deployments to be completed in early 2024 at ASP Cares Pharmacy in Las Vegas Agreement repsents expansion of successful relationship with Dallas-based Oak Lawn Pharmacy PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with Pharmacy Fund 1 for the deployment of ten M4 MedCenter kiosks, which will be serviced by ASP Cares Pharmacy. Pharmacy Fund 1 also operates Oaklawn Pharmacy, which is a current MedAvail partner in Dallas, Texas. Per the terms of the agreement, the first three MedCenters are planned to be deployed at First Person

      11/17/23 8:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Faulkner Robert C.

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      2/6/24 9:30:45 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Seabaugh Ramona converted options into 680 shares and sold $1,726 worth of shares (303 units at $5.70), increasing direct ownership by 45% to 1,222 units (SEC Form 4)

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      10/2/23 5:00:26 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Doerr Mark Edward

      4 - MedAvail Holdings, Inc. (0001402479) (Issuer)

      8/21/23 4:47:52 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    Financials

    Live finance-specific insights

    See more
    • MedAvail Reports Second Quarter 2023 Financial Results

      PHOENIX, Aug. 14, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the second quarter ended June 30, 2023. "During the second quarter, we were able to sustain the positive momentum that we have experienced since we began focusing on the immense market opportunity for our pharmacy technology in January of this year," said Mark Doerr, Chief Executive Officer of MedAvail. "Of note, we placed an additional two revenue generating MedCenters in the field, bringing our year-to-date total to six, and we reiterate our expectation that we will place 25 net new revenue generating MedCenters in

      8/14/23 4:49:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Reports First Quarter 2023 Financial Results

      PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the first quarter ended March 31, 2023. "During the first quarter, we made good progress toward our mission of becoming a leader in the development and manufacture of pharmacy technology solutions in the short time since we announced the sale of certain of our SpotRx assets to CVS in January," said Mark Doerr, Chief Executive Officer of MedAvail. "Our pipeline continues to grow, representing a mix of both new and existing partners, and we remain on track to achieve our previously stated goal of adding 25 net new dispe

      5/18/23 4:01:00 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail to Report First Quarter 2023 Financial Results on May 18

      PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets. MedAvail management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Call and webcast details:Thursday, May 18th, 2023 @ 4:30pm ETInvestor dial-in: 1- 877-704-4453 (domestic) or 1-201-389-0920 (international)Conference ID: 13738987To access the Call me™ feature, which avoids having to wait for an operator, click here. The live a

      5/18/23 7:00:00 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $MDVL
    SEC Filings

    See more
    • MedAvail Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      2/8/24 4:06:06 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      2/2/24 9:25:12 AM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • MedAvail Holdings Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - MedAvail Holdings, Inc. (0001402479) (Filer)

      1/23/24 4:38:20 PM ET
      $MDVL
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples